세계의 노인황반변성 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 질환별, 유통 채널별, 지역별, 부문별 예측(2024-2030년)

Age-related Macular Degeneration Market Growth & Trends:

The global age-related macular degeneration market size is expected to reach USD 17.99 billion by 2030, registering to grow at a CAGR of 8.2% from 2024 to 2030 according to a new report by Grand View Research, Inc. The growth is due to high R&D investments for new product development, product launches, rising age-related macular degeneration (AMD) prevalence, and the rising geriatric population.

There are no approved drugs available yet to treat dry age-related macular degeneration. This creates an opportunity for market players to address the unmet medical needs of dry AMD patients. However, for wet AMD, anti-VEGF drugs are used to treat and control the further deterioration of the condition.

Patients tend to discontinue their treatment without completion owing to frequent clinic visits and administration of drugs at shorter intervals. The key players are engaged in the research & development of longer acting anti-VEGF products to address the increased demand for such products. In February 2020, Novartis AG received approval for its product, Beovu, a macular degeneration drug from the European Commission for the treatment of patients with age-related macular generation. It is a long-acting drug to be administered at an interval of 12 weeks for the first year.

In addition, F. Hoffmann-La Roche Ltd.'s drug candidate, Vabysmo (faricimab), with an injection administration period of 4 weeks during loading dose; received U.S. FDA approval in January 2022 for the treatment of age-related macular degeneration. Furthermore, in October 2021, Roche's Susvimo received FDA approval and is expected to enter the U.S. in 2022. It is a refillable implant specific for LUCENTIS administration, with a refillable duration of six months. All these factors are expected to propel the market growth over the forecast period.

The patent expiry year for EYLEA is 2023 in the U.S. and 2025 in Europe, depending upon several patent categories. Lucentis (F. Hoffmann La Roche Ltd.) lost its patent in June 2020 in the U.S. and will lose patent protection in 2022 in Europe. As a result, biosimilar manufacturing companies are leveraging the opportunity to penetrate the AMD market. For instance, in October 2021, Formycon AG and Bioeq AG received the U.S. FDA acceptance of BLA for the company's biosimilar version of Lucentis. The PDUFA date for the review of the application is scheduled for August 2022. All these factors could hamper the market growth over the forecast period.

Age-related Macular Degeneration Market Report Highlights:

• The Eylea segment accounted for the largest market share of 47.7% in 2023. The market growth is attributed to patent protection and high market penetration. Eylea is prescribed for eye conditions that harm the retina or macula leading to impaired vision.
• The hospital pharmacy segment dominated the market and accounted for the largest share in 2023. This dominance can be attributed to the rise in the prevalence of age-related macular degeneration (AMD) and hospitalization for treatment.
• The wet AMD segment accounted for the largest market share in 2023. The growing geriatric population is one of the major factors influencing segment growth. According to Genentech, approximately 200,000 new instances of wet AMD are identified annually in North America.
• North America age-related macular degeneration market dominated the market in 2023. According to the American Academy of Ophthalmology, approximately 1.5 million Americans have late AMD, which is the vision-threatening type of AMD and 18.3 million Americans are affected by early AMD.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Age-Related Macular Degeneration Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Billion)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
  • 3.3.2. Market Restraints Analysis
• 3.4. Age-Related Macular Degeneration Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Age-Related Macular Degeneration Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Age-Related Macular Degeneration Market: Product Movement Analysis, USD Million, 2023 & 2030
• 4.3. Eylea
  • 4.3.1. Eylea Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Lucentis
  • 4.4.1. Lucentis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Beovu
  • 4.5.1. Beovu Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Other Products Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Age-Related Macular Degeneration Market: Disease Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Age-Related Macular Degeneration Market: Disease Movement Analysis, USD Million, 2023 & 2030
• 5.3. Wet AMD
  • 5.3.1. Wet AMD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Dry AMD
  • 5.4.1. Dry AMD Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Age-Related Macular Degeneration Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Age-Related Macular Degeneration Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
• 6.3. Hospital Pharmacy
  • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Specialty Pharmacy
  • 6.4.1. Specialty Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Online Pharmacy
  • 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Age-Related Macular Degeneration Market: Regional Estimates & Trend Analysis

• 7.1. Age-Related Macular Degeneration Market Share, By Region, 2023 & 2030, USD Million
• 7.2. North America
  • 7.2.1. North America Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. U.S. Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Canada Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Mexico Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. UK
    • 7.3.2.1. UK Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Germany
    • 7.3.3.1. Germany Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. France Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Italy Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Spain Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. China
    • 7.4.2.1. China Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Japan
    • 7.4.3.1. Japan Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. India Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. South Korea Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Australia Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Brazil Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Argentina Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Middle East and Africa
  • 7.6.1. Middle East and Africa Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Saudi Arabia
    • 7.6.2.1. Saudi Arabia Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. UAE
    • 7.6.3.1. UAE Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. South Africa
    • 7.6.4.1. South Africa Age-Related Macular Degeneration Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Heat Map Analysis
• 8.4. Company Profiles
  • 8.4.1. F. Hoffmann-La Roche Ltd
    • 8.4.1.1. Participant's Overview
    • 8.4.1.2. Financial Performance
    • 8.4.1.3. Product Benchmarking
    • 8.4.1.4. Recent Developments/ Strategic Initiatives
  • 8.4.2. Novartis AG
    • 8.4.2.1. Participant's Overview
    • 8.4.2.2. Financial Performance
    • 8.4.2.3. Product Benchmarking
    • 8.4.2.4. Recent Developments/ Strategic Initiatives
  • 8.4.3. Bayer AG
    • 8.4.3.1. Participant's Overview
    • 8.4.3.2. Financial Performance
    • 8.4.3.3. Product Benchmarking
    • 8.4.3.4. Recent Developments/ Strategic Initiatives
  • 8.4.4. Pfizer Inc.
    • 8.4.4.1. Participant's Overview
    • 8.4.4.2. Financial Performance
    • 8.4.4.3. Product Benchmarking
    • 8.4.4.4. Recent Developments/ Strategic Initiatives
  • 8.4.5. Bausch Health Companies Inc.
    • 8.4.5.1. Participant's Overview
    • 8.4.5.2. Financial Performance
    • 8.4.5.3. Product Benchmarking
    • 8.4.5.4. Recent Developments/ Strategic Initiatives
  • 8.4.6. Regeneron Pharmaceuticals Inc.
    • 8.4.6.1. Participant's Overview
    • 8.4.6.2. Financial Performance
    • 8.4.6.3. Product Benchmarking
    • 8.4.6.4. Recent Developments/ Strategic Initiatives
  • 8.4.7. Amgen Inc.
    • 8.4.7.1. Participant's Overview
    • 8.4.7.2. Financial Performance
    • 8.4.7.3. Product Benchmarking
    • 8.4.7.4. Recent Developments/ Strategic Initiatives
  • 8.4.8. Biogen
    • 8.4.8.1. Participant's Overview
    • 8.4.8.2. Financial Performance
    • 8.4.8.3. Product Benchmarking
    • 8.4.8.4. Recent Developments/ Strategic Initiatives
  • 8.4.9. Samsung Bioepis
    • 8.4.9.1. Participant's Overview
    • 8.4.9.2. Financial Performance
    • 8.4.9.3. Product Benchmarking
    • 8.4.9.4. Recent Developments/ Strategic Initiatives